OncoEthix in-licenses Mitsubishi Tanabe's cancer compound

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) granted OncoEthix S.A. (Lausanne, Switzerland) exclusive, worldwide rights to cancer compound OTX015. Mitsubishi retains rights to the compound ...